Six hot penny stocks to explore when Delta fear settles down

Summary

  • Oxford Square’s (NASDAQ: OXSQ) dividend yield is 8.68%. The stock gave a 29% return YTD.
  • Cinedigm Corp. (NASDAQ: CIDM) was selected for the Russell Microcap Index in June. The share grew 103% YTD. 
  • XpresSpa Inc. (NASDAQ: XSPA) provides diagnostic Covid-19 screening tests. The stock grew by 23% YTD.

Despite the threat of the Covid-19 Delta variant, the stock markets have been relatively stable. The optimism of a strong economic rebound has kept the investors in high spirits. While most growth stocks have lived up to their expectations over the past year, penny stocks have also been on investors' radar.

We explore here six penny stocks to know about their performance and future plans.

Oxford Square Capital Corp. (NASDAQ: OXSQ) is a non-diversified closed-end investment management company to provide the maximum return on the portfolio.

It has a market capitalization of US$237.57 million and a forward P/E for one year of 10.75.

OXSQ's current dividend yield is 8.68%, and its annualized dividend is US$0.42. The number of outstanding shares of common stock as of April 28, 2021, was 49,597,964.

Its revenue for the quarter ended March 31 was US$7.48 million, and net income applicable to common shareholders was US$21.79 million compared to the net loss of US$79.36 million in the same quarter of 2020. 

The stock gave a 29% return YTD at the closing price of US$1.08 on July 19, 2021.


Also Read: Top ten growth stocks in the USA

Source: Pixabay


Also Read: Take a look at top 10 global renewable energy stocks

Cinedigm Corp. (NASDAQ: CIDM) has a market capitalization of US$240.63 million. It is a consumer service company and provides various content to the media, technology, and retail companies. 

According to its preliminary results for the quarter ended March 31, 2021, announced this month, the consolidated revenue was US$8.3 million. CIDM’s total streaming minutes were roughly 1.16 billion, a 285% increase compared to the same quarter of 2020.

The company’s streaming channel distribution deals increased to 135, a 170% growth year-over-year, and live streaming channel brands increased to 16 from 13 in the same quarter of 2020.

It was selected for the Russell Microcap Index in June this year. The stock grew by 103% YTD. Its closing price on July 19 was US$1.36.

Also Read: US stocks are tumbling, but should you worry?

XpresSpa Group, Inc. (NASDAQ: XSPA) is a holding company and provides global travel health and wellness services. XpresSpa Group has two operating segments, XpresSpa and XpresTest.

The XpresSpa provides travelers spa services, and XpresTest provides diagnostic COVID-19 screening and testing at wellness centers in airports to airport employees and the traveling public.

It has a market cap of US$153.75 million.

For Q1 of 2021, it reported revenue of US$8.5 million compared to US$7.7 million in the same quarter in 2020, reflecting an increase of approximately 10% year-over-year. The company incurred a loss of US$1.06 million compared to US$10.62 in the same period the previous year, a decrease of 90%.

The stock grew by 23% YTD. The share closed at US$1.46 on July 19.

Also Read: 5 popular blockchain companies in the world

9 Meters Biopharma, Inc. (NASDAQ: NMTR) is a clinical-stage biopharmaceutical company focused on gastroenterology. NMTR develops medicines for inflammatory diseases. Its market cap is US$281.54 million.

The company has not generated revenue from product sales yet. In April, it closed a public offering of 34.5 million common stock shares. The net proceeds received were approximately US$31.5 million.

NMTR’s cash and cash equivalents were US$38.5 million as of March 31, 2021, compared to US$37.9 million in the December quarter of 2020.

It reported a net loss of US$5.4 million, or US$0.03 per share, for Q1, compared to a net loss of US$3.6 million, or US$0.09 per share, for the same quarter of 2020.

The stock rose 29% YTD at the closing price of US$1.08.

Also Read: Are these 10 global technology companies poised to grow in FY21?

aTyr Pharma, Inc. (NASDAQ: LIFE) is a biotherapeutics company. It develops medicines for the immune system. Its lead clinical product candidate is ATYR1923, a drug for inflammatory disease.

Its market cap is US$71.81 million.

LIFE has not generated revenue from its product sales and incurred a net loss attributable to the company of US$7.15 million compared to a net income of US$1.75 million in the previous year's March quarter. The stock grew 6% YTD, and it closed at US$4.22 on July 19, 2021.

Also Read: How do you find hyper-growth blue-chip stocks?

Source: Pixabay

Also Read: Top blue-chip stocks to explore in the US market

RYB Education, Inc. (NYSE: RYB) provides early childhood education in China. The company was founded in 1998 and headquartered in Beijing, China.

It has a market cap of US$136.55 million.

It announced unaudited first quarter results on July 7. Its revenue was US$36.7 million compared to US$17.3 million for the same quarter the previous year, representing a 111.8% increase.

Its net loss attributable to ordinary shareholders was US$1.8 million, compared to US$26.6 million for the corresponding period in 2020. 

RYB’s cash from operating activities was US$22.8 million for the March quarter of 2021 against US$14.0 million for the first quarter of 2020.


The stock rose 116% YTD at the closing price of US$4.93 on July 19, 2021.

Please note: The above constitutes a preliminary view, and any interest in stocks/cryptocurrencies should be evaluated further from an investment point of view.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

   

Kalkine

Rated 4.3/5 based on 904 Reviews at Google My Business